Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2018 07:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018

BURLINGTON, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2018 financial results after the close of the U.S....
October 22, 2018 07:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting

Data presented at 2018 American College of Rheumatology (ACR) Annual Meeting show concurrent, bilateral administration of ZILRETTA appeared safe and well toleratedSystemic exposure to triamcinolone...
October 05, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,600...
September 10, 2018 09:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology

Phase 2 data evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in patients with Type 2 diabetes demonstrated lower blood glucose levels following ZILRETTA injection...
September 07, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 10,500...
August 28, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference

BURLINGTON, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will present at the 13th Annual Wells Fargo Securities Healthcare Conference...
August 20, 2018 17:23 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium

Military Health System provides healthcare to more than nine million people; the research symposium highlights scientific advancements that impact military medicine Osteoarthritis is a leading cause...
August 07, 2018 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights

Company reported net ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) sales of $3.8 million in Q2 representing 73% growth over Q1Strong progress on the ZILRETTA commercial...
August 03, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to six new employees for an aggregate of 14,800...
July 30, 2018 16:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018

BURLINGTON, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2018 financial results after the close of the...